3 More Hidden Gems Nobody Owns While the Market Panics
While the internet argues about Jensen Huang's love life, these three small-caps are quietly building something interesting

Ticker Ratings
Look, everyone's had a big week. Jensen's gone, tankers are exploding in the Strait of Hormuz, and the FAA apparently runs on 1980s copper wire and vibes. It's the kind of news cycle that makes it really easy to miss the stocks quietly doing interesting things in the background. That's the job. Here are three under-the-radar names worth putting on your watchlist while the rest of the market stress-eats NVDA headlines.
$LGND (Ligand Pharmaceuticals) is a royalty-based biotech with a market cap under $3 billion that most people couldn't name in a lineup. It doesn't run clinical trials. It owns royalty interests in drugs that other companies develop, which means it collects revenue without taking on the full pipeline risk. That's a genuinely rare business model in biotech. The catalyst to watch: its royalty portfolio spans more than 15 approved products, and several late-stage partner programs are approaching FDA decision dates in 2027. If even one of those lands, royalty streams step up permanently. The bear case is straightforward: it's entirely dependent on partner execution, so if a key drug underperforms commercially, Ligand feels it without any operational lever to pull.
$MGNI (Magnite) is the largest independent sell-side advertising technology platform in the world, connecting publishers to programmatic ad buyers. Market cap sits around $1.5 billion. Nobody talks about it because it lives in the unsexy plumbing layer of digital advertising, the part between the ad buyer and the website. But connected TV ad spend is growing fast, and Magnite is deeply embedded in that pipe. The specific catalyst here is CTV budget migration: as linear TV continues to bleed viewers, that ad dollar has to go somewhere, and Magnite is positioned at that crossroads. The bear case is real competition pressure from The Trade Desk and Google's ad stack, which makes pricing power a constant question mark.
$IOBT (IO Biotech) is a clinical-stage immunotherapy company focused on a neoantigen-based cancer vaccine platform. With a market cap well under $500 million and a single lead program in melanoma, this is genuinely speculative, but the data readout expected in mid-2027 is the kind of binary event that can move a small-cap dramatically in either direction. The bull case is that cancer vaccines are having a serious scientific moment, and IO Biotech's approach targets multiple tumor antigens simultaneously, which is mechanistically differentiated. The bear case is everything that's always true about clinical-stage biotech: it might just not work.
Three totally different businesses, three totally different risk profiles. But all three share one thing: they're small enough that a single meaningful catalyst, a royalty step-up, a CTV budget surge, a phase 2 readout, can move the needle in a way that's simply impossible for a mega-cap. That's the whole game with hidden gems. The chaos is the opportunity.